The effect of long-term administration of analogs of luteinizing hormone-releasing hormone (LH-RH) and somatostatin on the growth of the growth hormone (GH)-and prolactin (PRL)-secreting rat pituitary GH3 tumor was investigated. Daily administration of tg/day) (Oss, Holland). Somatostatin analog cyclo(Pro-Phe-DTrp-Lys-Thr-Phe) (Veber cyclic hexapeptide) (12) was synthesized in our laboratory or supplied by J. Sandow and R. Geiger (Hoechst, Frankfurt M, FRG). Somatostatin analog D-Phe-Cys-Phe-t-Trp-Lys-Thr-Cys-Thr-NH2 related to the octapeptide of Bauer (13) was synthesized in our laboratory by solid-phase methods described previously (14).
GH3 pituitary tumor by more than 50% 6 or 13 wk after transplantation, *hen the tumors were fully developed. Serum GH and PRL levels also were reduced markedly by treatment with Previous extensive experimental and clinical studies have demonstrated a potential use of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone (LH-RH) for the treatment of various endocrine-dependent tumors (1) . This highly active agonistic analog of LH-RH has been shown to exert paradoxical inhibitory effects on the pituitary-gonadal axis in both animals and human beings when given chronically (2, 3) . This inhibition of reproductive functions produced by chronic administration of LH-RH and other LH-RH agonists has been utilized to induce a regression of various hormone-sensitive neoplasms such as mammary carcinomas, prostate tumors, and pituitary tumors (4) (5) (6) (7) . It has been shown that long-te~rm administration of agonistic and antagonistic analogs of LH-RH inhibited the growth of the 7315a transplantable rat pituitary tumor, which secretes both prolactin (PRL) and corticotropin (ACTH) (6, 7) . In order to study further the inhibitory effect of [D-Trp6]LH-RH on pituitary tumors, we decided to extend our investigations to the PRL-and growth hormone (GH)-producing GH3 rat pituitary tumor. This transplantable pituitary tumor is a clonal strain derived from an ACTH/GH-secreting tumor (8) . It shares many characteristics of normal pituitary cells but responds poorly to therapy with dopamine agonists such as 2-bromo-a-ergocryptine (called bromocriptine) (9) . Treatmeflt of some human pituitary tumors with bromocriptine does not invariably result in clinical improvement, suggesting an insensitivity of this type of tumor to DA agonists therapy (.10). (ORG 30276 ) was obtained from Organon (Oss, Holland). Somatostatin analog cyclo(Pro-Phe-DTrp-Lys-Thr-Phe) (Veber cyclic hexapeptide) (12) was synthesized in our laboratory or supplied by J. Sandow and R. Geiger (Hoechst, Frankfurt M, FRG). Somatostatin analog D-Phe-Cys-Phe-t-Trp-Lys-Thr-Cys-Thr-NH2 related to the octapeptide of Bauer (13) was synthesized in our laboratory by solid-phase methods described previously (14) . Five to seven animals were used per experimental group. In the first experiment, the treatment with peptides was started before tumors appeared, while in subsequent experiments, peptide administration was initiated when 50-100% of the animals showed well-developed tumors. Tumors were measured weekly with microcalipers and tumor volumes were calculated as described (7) 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. tide (Pro-Phe-D-Trp-Lys-Thr-Phe) or modified Bauer somatostatin octapeptide D-Phe-Cys-Phe-D-Trp-Lys-Thr-CysThr-NH2 produced an increase in serum PRL and GH levels and decreased pituitary GH levels. Treatment with [DTrp6WLH-RH also reduced serum progesterone, 17-f3-estradiol, and insulin levels in these animals (P < 0.05, P < 0.01, and P < 0.005, respectively) ( Table 3 ). The effect of administration of LH-RH analogs on rats bearing well-developed GH3 tumors was investigated next. The treatment was started when 50% of the animals had well-developed tumors. Administration of [D-Trp6]LH-RH microcapsules resulted in a reduction of tumor growth of more than 50%, as indicated by the reduced increment in tumor volume (P < 0.05), decreased tumor weight (P = 0.05) ( Table 4 , experiment II), and lower tumor incidence (67%). Ovarian weights were again decreased by [ Table 4 , experiment II) produced only a small and not significant decrease in tumor volume and weight and caused no change in tumor incidence rate. In agreement with the results of experiment I ( The mechanism(s) by which [D-Trp6]LH-RH and other analogs of LH-RH inhibited the growth of the estrogen-dependent ACTH/PRL-producing 7315a rat pituitary tumor has been linked to the suppression of sex steroids levels (6, 7) . In the present study with GH3 pituitary tumor, we have also found that the levels of sex steroids were greatly depressed gland more effectively to the agonist, whereas twice-a-day injections of the agonist still allow the gland to respond to the stimulatory effect of the peptide with the release of immunoreactive LH (11) . A greater efficacy of microcapsules as compared with daily injections also was established previously in our study with rat prostate tumors (11) . Our clinical results also attest to the high efficacy of microcapsules (11) . In addition, the immunoreactive LH produced after chronic stimulation with LH-RH agonists was reported to have decreased biological activity (18, 19) .
In any case, ovarian suppression after chronic [D-Trp6]LH-RH administration may occur in the presence of high immunoreactive serum LH levels (18, 19) . However, the antitumoral activity of [D-Trp6]LH-RH could be related in part to a direct action on this agonist on the pituitary tumor cells.
The GH3 pituitary cells have been reported to possess receptors for somatostatin (20) and to be unresponsive to GH-RH stimulation (21) . Interestingly, the somatostatin analogs used in this study did not inhibit tumor growth, but rather enhanced it under our conditions. Serum PRL and GH levels were elevated over control values in animals treated with the Veber cyclic hexapeptide or the somatostatin octapeptide related to the Bauer analog. Only pituitary GH levels were reduced by the somatostatin analogs, suggesting that the peptides impaired the activity of the normal somatotrophic cell without affecting the growth of GH3 cells. On the other hand, we have shown previously that the D-5-methoxytryptophan-8 analog of somatostatin inhibited the growth of the pituitary tumor 7315a (7) . Furthermore, the original Bauer octapeptide (13) was recently reported to decrease high GH levels and to inhibit tumor growth in a patient with a GH-RH-secreting tumor of the gut (22) . Thus, it appears that some, but not all, pituitary tumors can be affected by administration of somatostatin analogs.
In conclusion, administration of [D-Trp6]LH-RH inhibits the growth of the GH-and PRL-secreting GH3 pituitary tumor. The exact mechanism(s) through which this effect is exerted are not clear, but the suppression of ovarian functions or a direct action of the analog might be partially involved in this inhibition. The fact that [D-Trp6]LH-RH can inhibit prolactin levels in ovariectomized animals treated with haloperidol suggests that the suppression of the pituitary-ovarian axis is not necessary for this response (23 
